Drug-induced psychosis following use of Ayahuasca: a presentation to forensic psychiatric services.

Ayahuasca is a plant-based psychoactive decoction, traditionally used by indigenous Amazonian peoples, which commonly contains the hallucinogen N,N-dimethyltryptamine (DMT). There is now growing interest across the Western world in psychedelics including Ayahuasca.This case describes a previously well male with no risk factors for adverse psychiatric outcomes or forensic history. Following controlled Ayahuasca use, he developed an enduring psychotic episode, during which he significantly assaulted a relative and was admitted to a forensic psychiatric unit. He was treated with the antipsychotic aripiprazole, and his psychotic symptoms abated. 18 months following his admission, recovery has been sustained.Previous case reports have described psychosis following Ayahuasca ingestion, but typically of short duration in patients with a personal or family history of psychiatric illness, or in those taking other substances. With the growing use of Ayahuasca, it is important to highlight that adverse effects may include more prolonged psychotic symptoms and the risk of psychotically mediated violence.

Effects of a Single Dose of Ayahuasca in College Students With Harmful Alcohol Use: A Single-blind, Feasibility, Proof-of-Concept Trial.

BACKGROUND: Ayahuasca is a South American plant hallucinogen rich in the psychedelic N,N-dimethyltryptamine and ß-carbolines (mainly harmine). Preclinical and observational studies suggest that ayahuasca exerts beneficial effects in substance use disorders, but these potentials were never assessed in a clinical trial. METHODS: Single-center, single-blind, feasibility, proof-of-concept study, assessing the effects of one dose of ayahuasca accompanied by psychological support (without psychotherapy) on the drinking patterns (primary variable) of 11 college students with harmful alcohol consumption. Secondary variables included safety and tolerability, craving, personality, anxiety, impulsivity, self-esteem, and social cognition. FINDINGS: Ayahuasca was well tolerated (no serious adverse reactions were observed), while producing significant psychoactive effects. Significant reductions in days per week of alcohol consumption were found between weeks 2 and 3 (2.90 ± 0.28 vs 2.09 ± 0.41; P < 0.05, uncorrected), which were not statistically significant after Bonferroni correction. There were no statistically significant effects for other variables, except for a significant reduction in reaction time in an empathy task. CONCLUSIONS: A significant reduction in days of alcohol consumption was observed 2-3 weeks after ayahuasca intake, but this effect did not survive after Bonferroni correction. The lack of significant effects in alcohol use and other variables may be related to the small sample size and mild/moderate alcohol use at baseline. The present study shows the feasibility of our protocol, paving the way for future larger, controlled studies.

The psychedelic call: analysis of Australian Poisons Information Centre calls associated with classic psychedelics.

INTRODUCTION: The global use of certain classical psychedelics has increased in recent years, but little is known about their spectrum of toxicity within Australia. We aim to describe calls to New South Wales Poisons Information Centre relating to exposures to classical psychedelics including lysergic acid diethylamide, psilocybin, N,N-dimethyltryptamine, ayahuasca, mescaline and ibogaine. METHODS: This is a retrospective observational study of calls to New South Wales Poisons Information Centre between January 2014 and December 2022. We identified exposures to classical psychedelics within New South Wales Poisons Information Centre database and measured the annual number of exposures, source of call (hospital, health care worker, member of the public), co-ingested substances, clinical features and advice given. RESULTS: There were 737 calls related to relevant psychedelic exposures; 352 (47.8 per cent) to lysergic acid diethylamide, 347 (47.0 per cent) to psilocybin, 28 (3.8 per cent) to N,N-dimethyltryptamine, 4 (0.5 per cent) to ayahuasca, 4 (0.5 per cent) to mescaline and 2 (0.3 per cent) to ibogaine. Cases were predominantly male (77.2 per cent) and aged between 20 and 74 years (65.6 per cent). Psychedelic calls more than doubled from 45 in 2014 to 105 in 2022 and 625 (85 per cent) of all calls were either from or referred to hospital. Co-ingestion of psychedelics with another substance occurred in 249 (33.8 per cent) of calls and the most frequent clinical features related to single substance psychedelic exposures were hallucinations (27.6 per cent), gastrointestinal symptoms (21.7 per cent) and tachycardia (18.1 per cent). Seizures occurred in 2.9 per cent of single substance psychedelic exposures. DISCUSSION: Increasing incidence of psychedelic exposure calls, including those reporting significant toxicity, likely reflects increasing community use. This may in part be driven by increasing interest in psychedelic assisted psychotherapy trials subsequently increasing public awareness. CONCLUSION: Relatively high poisoning severity contrasts with safety within clinical trials of psychedelic assisted psychotherapy that may relate to the uncontrolled nature of community use which is mitigated within clinical trial environments. Education about safe use may be useful.

Comparative study of sample preparation procedures to determine the main compounds in ayahuasca beverages by QuEChERS and high-performance liquid chromatography analysis.

INTRODUCTION: Ayahuasca is a psychoactive drink originally consumed by indigenous people of the Amazon. The lack of regulation of this drink leads to uncontrolled consumption, and it is often consumed in religious contexts. OBJECTIVE: The aim of this work is to compare three miniaturised extraction techniques for extracting the main ayahuasca compounds from beverages. METHODOLOGY: Three sample pretreatment techniques were evaluated (dispersive liquid-liquid microextraction [DLLME], microextraction by packed sorbent [MEPS] and QuEChERS [Quick, Easy, Cheap, Effective, Rugged and Safe]) for the simultaneous extraction of N,N-dimethyltryptamine (DMT), tetrahydroharmine (THH), harmine, harmaline, harmol and harmalol from ayahuasca beverage samples. Then, the most promising technique (QuEChERS) was chosen to pre-concentrate the analytes, subsequently detected by high-performance liquid chromatography coupled to a diode array detector (HPLC-DAD). RESULTS: The procedure was optimised, with the final conditions being 500 µL of extractor solvent, 85 mg of primary secondary amine (PSA) and 4 s of vortexing. The analytical method was validated, showing to be linear between 0.16 and 10 µg/mL for ß-carbolines and between 0.016 and 1 µg/mL for DMT, with coefficients of determination (R2) between 0.9968 and 0.9993. The limit of detection (LOD) and lower limit of quantification (LLOQ) were 0.16 µg/mL for all compounds, except for DMT (0.016 µg/mL) and extraction efficiencies varied between 60.2% and 88.0%. CONCLUSION: The analytical methodology proved to be accurate and precise, with good linearity, LODs and LLOQs. This method has been fully validated and successfully applied to ayahuasca beverage samples.

Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis.

We aim to systematically review and meta-analyze the effectiveness and safety of psychedelics [psilocybin, ayahuasca (active component DMT), LSD and MDMA] in treating symptoms of various mental disorders. Web of Science, Embase, EBSCO, and PubMed were searched up to February 2024 and 126 articles were finally included. Results showed that psilocybin has the largest number of articles on treating mood disorders (N = 28), followed by ayahuasca (N = 7) and LSD (N = 6). Overall, psychedelics have therapeutic effects on mental disorders such as depression and anxiety. Specifically, psilocybin (Hedges' g = -1.49, 95% CI [-1.67, -1.30]) showed the strongest therapeutic effect among four psychedelics, followed by ayahuasca (Hedges' g = -1.34, 95% CI [-1.86, -0.82]), MDMA (Hedges' g = -0.83, 95% CI [-1.33, -0.32]), and LSD (Hedges' g = -0.65, 95% CI [-1.03, -0.27]). A small amount of evidence also supports psychedelics improving tobacco addiction, eating disorders, sleep disorders, borderline personality disorder, obsessive-compulsive disorder, and body dysmorphic disorder. The most common adverse event with psychedelics was headache. Nearly a third of the articles reported that no participants reported lasting adverse effects. Our analyses suggest that psychedelics reduce negative mood, and have potential efficacy in other mental disorders, such as substance-use disorders and PTSD.

Psychedelic Therapy: A Primer for Primary Care Clinicians-N,N-Dimethyltryptamine and Ayahuasca.

BACKGROUND: N,N-dimethyltryptamine (DMT) is a naturally occurring serotonergic psychedelic found in natural plants around the globe. As the main psychoactive component in ayahuasca, which also contains monoamine oxidase inhibitors, DMT has been consumed as plant-based brew by indigenous peoples for centuries. Further research is required to delineate the therapeutic utility of DMT. AREAS OF UNCERTAINTY: Although previous research has shown that DMT is synthesized endogenously, it may not be produced at physiologically relevant concentrations. Additionally, the phenomenological similarities between the DMT-induced state and near-death experiences led to the popular hypothesis that endogenous DMT is released during the dying process. However, this hypothesis continues to be debated. Generally, DMT and ayahuasca seem to be physiologically and psychiatrically safe, although ayahuasca is known to cause transient vomiting. THERAPEUTIC ADVANCES: A double-blind, randomized controlled trial showed that, within 1 week, ayahuasca causes remission in 36% of patients with treatment-resistant depression. According to top-line results from a recent phase IIa trial, 57% of patients with major depressive disorder experienced remission 12 weeks after receiving a single intravenous dose of DMT. LIMITATIONS: There has only been a single published double-blind randomized controlled trial on ayahuasca and 2 on DMT. All clinical trials have had small sample sizes (≤34 participants). DMT requires further research to understand its therapeutic and clinical potential as a psychedelic. CONCLUSIONS: Preliminary evidence indicates that ayahuasca and DMT may be more effective than existing antidepressants for treating major depressive disorder and treatment-resistant depression.

Ayahuasca and Dimethyltryptamine Adverse Events and Toxicity Analysis: A Systematic Thematic Review.

The objective of this paper is to conduct a systematic thematic review of adverse events, safety, and toxicity of traditional ayahuasca plant preparations and its main psychoactive alkaloids (dimethyltryptamine [DMT], harmine, harmaline, and tetrahydroharmine), including discussing clinical considerations (within clinical trials or approved settings). A systematic literature search of preclinical, clinical, epidemiological, and pharmacovigilance data (as well as pertinent reviews and case studies) was conducted for articles using the electronic databases of PubMed and Web of Science (to 6 July 2023) and PsycINFO, ClinicalTrials.gov, and Embase (to 21 September 2022) and included articles in English in peer-reviewed journals. Additionally, reference lists were searched. Due to the breadth of the area covered, we presented the relevant data in a thematic format. Our searches revealed 78 relevant articles. Data showed that ayahuasca or DMT is generally safe; however, some adverse human events have been reported. Animal models using higher doses of ayahuasca have shown abortifacient and teratogenic effects. Isolated harmala alkaloid studies have also revealed evidence of potential toxicity at higher doses, which may increase with co-administration with certain medications. Harmaline revealed the most issues in preclinical models. Nevertheless, animal models involving higher-dose synthetic isolates may not necessarily be able to be extrapolated to human use of therapeutic doses of plant-based extracts. Serious adverse effects are rarely reported within healthy populations, indicating an acceptable safety profile for the traditional use of ayahuasca and DMT in controlled settings. Further randomized, controlled trials with judicious blinding, larger samples, and longer duration are needed.

Ayahuasca-enhanced extinction of fear behaviour: Role of infralimbic cortex 5-HT2A and 5-HT1A receptors.

BACKGROUND AND PURPOSE: Ayahuasca (AYA) is a botanical psychedelic with promising results in observational and small clinical trials for depression, trauma and drug use disorders. Its psychoactive effects primarily stem from N,N-dimethyltryptamine (DMT). However, there is a lack of research on how and where AYA acts in the brain. This study addressed these questions by examining the extinction of aversive memories in AYA-treated rats. EXPERIMENTAL APPROACH: We focused on the 5-HT1A and 5-HT2A receptors, as DMT exhibits a high affinity for both of them, along with the infralimbic cortex in which activity and plasticity play crucial roles in regulating the mnemonic process under analysis. KEY RESULTS: A single oral treatment with AYA containing 0.3 mg·kg-1 of DMT increased the within-session extinction of contextual freezing behaviour without affecting its recall. This protocol, when repeated twice on consecutive days, enhanced extinction recall. These effects were consistent for both 1- and 21-day-old memories in males and females. AYA effects on fear extinction were independent of changes in anxiety and general exploratory activity: AYA- and vehicle-treated animals showed no differences when tested in the elevated plus-maze. The 5-HT2A receptor antagonist MDL-11,939 and the 5-HT1A receptor antagonist WAY-100635 infused into the infralimbic cortex respectively blocked within- and between-session fear extinction effects resulting from repeated oral administration of AYA. CONCLUSION AND IMPLICATIONS: Our findings highlight complementary mechanisms by which AYA facilitates the behavioural suppression of aversive memories in the rat infralimbic cortex. These results suggest potential beneficial effects of AYA or DMT in stress-related disorders.

Ayahuasca and its major component harmine promote antinociceptive effects in mouse models of acute and chronic pain.

ETHNOPHARMACOLOGICAL RELEVANCE: Ayahuasca (AYA) is a psychedelic brew used in religious ceremonies. It is broadly used as a sacred medicine for treating several ailments, including pain of various origins. AIM OF THE STUDY: To investigate the antinociceptive effects of AYA and its mechanisms in preclinical models of acute and chronic pain in mice, in particular during experimental neuropathy. MATERIALS AND METHODS: The antinociceptive effects of AYA administered orally were assessed in the following models of pain: formalin test, Complete Freund's Adjuvant (CFA)-induced inflammation, tail flick test, and partial sciatic nerve ligation model of neuropathic pain. Antagonism assays and Fos immunohistochemistry in the brain were performed. AYA-induced toxicity was investigated. AYA was chemically characterized. The antinociceptive effect of harmine, the major component present in AYA, was investigated. RESULTS: AYA (24-3000 µL/kg) dose-dependently reduced formalin-induced pain-like behaviors and CFA-induced mechanical allodynia but did not affect CFA-induced paw edema or tail flick latency. During experimental neuropathy, single treatments with AYA (24-3000 µL/kg) reduced mechanical allodynia; daily treatments once or twice a day for 14 days promoted consistent and sustained antinociception. The antinociceptive effect of AYA (600 µL/kg) was reverted by bicuculline (1 mg/kg) and methysergide (5 mg/kg), but not by naloxone (5 mg/kg), phaclofen (2 mg/kg), and rimonabant (10 mg/kg), suggesting the roles of GABAA and serotonergic receptors. AYA increased Fos expression in the ventrolateral periaqueductal gray and nucleus raphe magnus after 1 h, but not after 6 h or 14 days of daily treatments. AYA (600 µL/kg) twice a day for 14 days did not alter mice's motor function, spontaneous locomotion, body weight, food and water intake, hematological, biochemical, and histopathological parameters. Harmine (3.5 mg/kg) promoted consistent antinociception during experimental neuropathy. CONCLUSIONS: AYA promotes consistent antinociceptive effects in different mouse models of pain without inducing detectable toxic effects. Harmine is at least partially accountable for the antinociceptive properties of AYA.

Relatos de exploradores e viajantes e primeiras pesquisas científicas com a ayahuasca, 1850-1950, no debate atual sobre o "renascimento psicodélico" / Reports by explorers and travelers and the first scientific studies on ayahuasca (dating from 1850 to 1950) within the current debate on the "psychedelic renaissance"

Resumo O artigo descreve associações e controvérsias entre usos indígenas e ocidentais da ayahuasca, de 1850 a 1950, na relação com o "renascimento psicodélico". Destaque na ciência desde 2000, esse movimento faz referência a 1960-1970, quando políticas antidrogas suspenderam pesquisas sobre "potenciais terapêuticos" de substâncias psicoativas. Argumenta-se que estudos pioneiros com a ayahuasca datam do início do século XX e mencionam relatos de expedições à Amazônia desde 1850. Esses artigos e relatos são analisados pelo aspecto histórico da teoria do ator-rede e de estudos recentes. Infere-se que a história ilumina o debate político atual sobre os usos, classificações e significados indígenas; o interesse farmacêutico na ayahuasca; e a discussão sobre "drogas".

Abstract This article describes the associations and controversies between indigenous and western uses of ayahuasca between 1850 and 1950 in relation to the "psychedelic renaissance." This movement has gained scientific attention since 2000, but hearkens back to the 1960s and 1970s, when anti-drug policy halted research on the "therapeutic potential" of psychoactive substances. Pioneering studies on ayahuasca date back to the early twentieth century and mention reports of expeditions to Amazonia from 1850 onward. Here, these articles and reports are analyzed according to the historical aspect of actor-network theory and recent studies. We infer that history casts light on the current political debate about indigenous uses, classifications, and meanings, pharmaceutical interest in ayahuasca, and the debate on "drugs."

Behavioral characterization of ayahuasca treatment on Wistar rats in the open field test

Abstract Ayahuasca (AYA) is a psychedelic beverage with therapeutic potential for many mood and anxiety disorders. Although there are some preclinical studies, no published reports have tested the behavioral effects of AYA gavage in animal models. This investigation aimed to characterize the behavior of Wistar rats after acute ingestion of AYA for 40 min in the open field test (OFT). The sample consisted of three experimental groups treated with different dosages of AYA (125, 250, or 500 mg kg-1) and a control group. Each group consisted of 10 participants. After gavage, the number of crossings of the OFT grid lines, latency to enter the central area of the device, grooming frequency, and time spent in the central perimeter of the device were immediately evaluated. Analyses were based on one-way ANOVA and a linear-regression mixture model for longitudinal data. AYA intake did not interfere with habituation. The 500 mg kg-1 group showed a decrease in the time spent in the center of the device and in the number of crossings compared to the control group in the last 10 min. These results suggest that gavage with AYA did not interfere with the results, and the behavioral effects were perceived only between 30 and 40 min after gavage. Taken together, the results indicate that three aspects should be considered in OFT studies of AYA acute effects: the moment when the observation starts, the observation period, and the AYA dosage.

Temperamento dos adeptos do uso ritual da Ayahuasca do Centro Luz Divina, Piedade –SP, Brasil / Temperament of the adepts of the ritual use of Ayahuasca at the Centro Luz Divina, Piedade -SP, Brazil

O temperamento pode ser considerado a base do humor, do comportamento e da personalidade do indivíduo. Assim, o objetivo deste estudo foi verificar a influência do consumo ritual da Ayahuasca pelos adeptos daimistas do Centro Luz Divina, em relação ao temperamento de usuários experientes e iniciantes. Foi realizado um estudo transversal, do qual participaram 48 pessoas, distribuídas em dois grupos: (a) grupo estudo: subdividido em grupo experiente (16 pessoas com mais de 20 anos de uso ritual da Ayahuasca) e grupo iniciante (16 pessoas com menos de 3 anos de uso ritual); (b) grupo controle (16 pessoas que nunca utilizaram Ayahuasca), pareado por sexo, faixa etária e escolaridade. Foi utilizada a Escala Composta de Temperamento Emocional e Afetivo(AFECTS). Observou-se efeito significante entre os grupos na dimensão emocional Vontade [F(2,48)= 4,75; p=0,013],ressalte-se que o grupo experiente (47,00) obteve melhor pontuação que o grupo controle (42,68). Verificou-se o efeito da interação entre grupo e sexo na dimensão emocional Controle [F(5,48)= 7,04; p=0,002], grupo feminino experiente (46,50) versus grupo feminino controle (39,87). Considerando apenas o grupo estudo (experiente e iniciante), constatou-se: correlação positiva da dimensão emocional Vontade com Maturidade (coping) e Estabilidade; correlação positiva da dimensão emocional Controle com Maturidade (coping), Estabilidade e Cautela, e negativa com Raiva. Em conclusão, todas as mulheres do grupo experiente obtiveram classificação do temperamento “Estáveis”e atingiriam escores significativos na dimensão emocional Controle, enquanto o grupo experiente, de ambos os sexos, sobressaiu-se na dimensão emocional Vontade.(AU)

Temperament can be considered the basis of the individual’s humor, behavior and personality. The aim of this study was to verify the influence of Ayahuasca’s ritual consumption, by the daimist adepts of Centro Luz Divina, in relation to the temperament of experienced users and beginners. A cross-sectional study in which 48 people participated was performed. They were distributed into two groups of 16 people: (a) study group subdivided into an experienced group (16 people with over 20 years of Ayahuasca’s ritual use) and a beginners group (16 people with less than 3 years of ritual use); (b) control group (16 people who never used ayahuasca) paired by sex, age and scholarity. The Affective and Emotional Composite Temperament Scale (AFECTS) was applied. A significant effect was observed in the Volition dimension [F(2,48)= 4,75; p = 0,013]. The score of the experience group (47,00) was higher than the control group (42,68). It was verified the effect of the interaction between group and sex in the Control dimension [F(5,48)= 7,04; p = 0,002]: experienced female group (46,50) versuscontrol female group (39,87). Considering only the study group (both experienced and beginners) it was verified: positive correlation of the Volition dimension with Coping and Stability; positive correlation of the Control dimension with Coping, Stability and Caution, and negative correlation with Anger. In conclusion, all women in the experienced group obtained “stable” temperament rating and achieved significant scores in the emotional dimension Control; while the experienced group, of both genders, stood out in the emotional dimension Volition.(AU)

Psychosis induced by abuse of ayahuasca: a case report / Psicosis inducida por el abuso de la ayahuasca: un caso clínico

A B S T R A C T Ayahuasca is a psychotropic infusion prepared by boiling the bark of Amazonian plants and has many psychopharmacological effects not fully understood. Some of those effects are used as treatment for different diseases. However, the side effects of ayahuasca, including ayahuasca-induced psychosis, are an important issue. Here we report the case of a patient who had a psychotic episode after taking ayahuasca and who was successfully treated with antipsychotic medication. Given the current spread of ayahuasca consumption in developed societies, the present case highlights the need for better understanding and regulation of the social-legal condition of ayahuasca and the need for further research. Additionally, psycho-education seems advisable in order to create awareness of the potential risks of the use of ayahuasca.

RESUMEN La ayahuasca es una bebida psicotrópica preparada a través de la cocción de plantas de la cuenca amazónica que tiene muchos efectos psicofarmacológicos no del todo estudiados. Algunos de esos efectos son usados como tratamiento de diversas patologías. Sin embargo, existen efectos secundarios de la ayahuasca que deben ser tenidos en cuenta, entre ellos psicosis inducida por ayahuasca. Reportamos un caso de un paciente que, tras autoadministración de ayahuasca, presentó un episodio psicótico y que fue satisfactoriamente tratado con antipsicóticos. Dada el uso cada vez más frecuente de ayahuasca en las sociedades desarrolladas, el caso actual resalta las necesidades de entender, regular e investigar el uso de la ayahuasca. Además, crear conciencia de los potenciales riesgos del uso de ayahuasca a través de la psicoeducación debería ser implementado.

The pharmacological interaction of compounds in ayahuasca: a systematic review

Ayahuasca is a South American psychoactive plant brew used as traditional medicine in spiritual and in cultural rituals. This is a review of the current understanding about the pharmacological mechanisms that may be interacting in ayahuasca. Searches were performed using PubMed, PsycINFO, and Web of Science databases and 16 papers were selected. As hypothesized, the primary narrative in existing research revolved around prevention of deamination of N,N-dimethyltryptamine (N,N-DMT, also referred to as DMT) by monoamine oxidase inhibitors (MAOIs) in ayahuasca. Two of the constituents, DMT and harmine, have been studied more than the secondary harmala alkaloids. At present, it is unclear whether the pharmacological interactions in ayahuasca act synergistically or additively to produce psychoactive drug effects. The included studies suggest that our current understanding of the preparation's synergistic mechanisms is limited and that more complex processes may be involved; there is not yet enough data to determine any potential synergistic interaction between the known compounds in ayahuasca. Our pharmacological understanding of its compounds must be increased to avoid the potential risks of ayahuasca use.

Compreensão de sentidos atribuídos à ayahuasca: percursos terapêuticos do uso ritualístico / Understanding of meanings attributed to ayahuasca: therapeutic paths of ritual use / Comprensión de los sentidos atribuidos a la ayahuasca: recorridos terapéuticos del uso ritual

Ayahuasca é uma bebida psicoativa de origem amazônica preparada a partir do cipó conhecido como jagube e/ou mariri (Banisteriopsis caapi) e do arbusto chacrona (Psychotria viridis). Seu uso cultural e ritualístico tem reconhecimento milenar por etnias indígenas da Amazônia Ocidental e ganhou influência mundial na década de 1980, por meio da expansão do seu uso religioso. No campo biomédico, estudos têm atestado a segurança na administração da bebida em humanos e encontraram características de bem-estar físico e mental em usuários. Este artigo tem como objetivo discutir os resultados de uma pesquisa que investigou histórias de vida de pessoas com itinerários terapêuticos ligados ao uso ritualístico da ayahuasca, a partir de uma compreensão fenomenológica-existencial e da gestalt-terapia. A metodologia de trabalho baseou-se na postura fenomenológica e no método de história de vida, possibilitando uma apreensão da experiência vivida nos rituais. Verificou-se, assim, que as experiências ritualísticas e os itinerários terapêuticos contribuíram no reconhecimento dos participantes de que a saúde é uma postura de maturidade ou sabedoria associada a suas relações com o mundo, atribuindo à ayahuasca a capacidade de operar ressignificações no processo cotidiano do autocuidado e, acima de tudo, no amor a si mesmos.

Ayahuasca is a psychoactive drink of Amazonian origin prepared from vine known as jagube and/or mariri (Banisteriopsis caapi) and chacrona bush (Psychotria viridis). Its cultural and ritualistic use have been recognized from millennia by indigenous ethnic groups in the Western Amazon and gained worldwide influence in the 1980s through the expansion of it religious use. In the biomedical field, studies have attested the safety in the administration of the beverage in humans and found features of physical and mental wellbeing on users. This article aims to discuss the results of a research that investigated life histories of people with therapeutic itineraries connected to the ritualistic use of ayahuasca, from a phenomenological-existential understanding and gestalt-therapy approach. The methodology was based on a phenomenological stance and in life history method, enabling an apprehension of lived experience of the rituals. Thus, it was verified that the ritualistic experiences and the therapeutic itineraries contributed in the participants' recognition that health is a posture of maturity or wisdom associated to their relations with the world, attributing to ayahuasca the capacity to operate re-significations in the daily process of self-care and, above all, in love of oneself.

Ayahuasca es una bebida psicoactiva de origen amazónico, preparado a partir de la cepa jagube o mariri (Banisteriopsis caapi) y del arbusto chacrona (Psychotria viridis). Su uso cultural y ritual tiene reconocimiento milenario de etnias indígenas de la Amazonia occidental y ha ganado influencia mundial en la década de 1980, mediante la expansión de su uso religioso. En el campo biomédico, los estudios garantizaron seguridad en la administración de la bebida en humanos y encontraron características de bienestar mental y físico en sus usuarios. El objetivo es discutir los resultados de una investigación de la historia de vida de personas con recurridos terapéuticos de uso ritual de ayahuasca, desde una comprensión fenomenológica-existencial y de la terapia gestáltica. La metodología se basa en la actitud fenomenológica y en el método de historia de vida, lo que permite una aprehensión de la experiencia vivida. Así, se verificó que las experiencias rituales y los recurridos terapéuticos contribuyeron al reconocimiento de los participantes de que la salud es una postura de madurez o sabiduría asociada a sus relaciones con el mundo, atribuyendo a la ayahuasca la capacidad de operar resignificaciones en el proceso diario de autocuidado y, sobre todo, de amor a sí mismo.

Ayahuasca Homeopatia / Ayahuasca Homeopathy

Trabalho realizado a partir de uma revisão da literatura da bebida Ayahuasca, um chá que é produzido a partir de duas plantas e é utilizada em contextos religiosos no Brasil desde 1930 para o processo de expansão da consciência e conexão com o divino e também como auxiliar em tratamentos de depressão, uso de drogas, alcoolismo, câncer e diversas doenças. O objetivo desse estudo é verificar a literatura existente e também as pesquisas e trabalhos com a Ayahuasca e a Matéria Médica Homeopática para auxiliar em estudos futuros e projetos de pesquisas para a experimentação patogenética da Ayahuasca e então a criação de um novo medicamento homeopático, a Homeopatia da Ayahuasca.(AU)

Work carried out from a review of the literature on the Ayahuasca drink, a tea that is produced from two plants and has been used in religious contexts in Brazil since 1930 for the process of expanding consciousness and connecting with the divine and also as an aid in depression treatments, drug use, alcoholism, cancer and various diseases. The objective of this study is to verify the existing literature and also the research and work with Ayahuasca and the Materia Medica Homeopathic to assist in future studies and research projects for the pathogenic experimentation of Ayahuasca and then the creation of a new homeopathic medicine, Homeopathy of Ayahuasca.(AU)